XORTX Therapeutics is focused on developing innovative therapies to treat progressive kidney disease. The Company has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. XORTX is dedicated to advancing treatments that improve the care and quality of life of patients suffering from these life-threatening diseases. Our development programs currently focus on potential treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and Diabetic Nephropathy (DN).

XORTX has received an important endorsement of its programs from the PKD Foundation (www.pkdcure.org) and is collaborating with the foundation. This collaboration will help advance XORTX’s programs to define the beneficial effects of XORTX’s therapies, in ADPKD patients but potentially in other forms of polycystic kidney disease as well. XORTX believes that there are substantial benefits to working with the leading polycystic kidney disease foundation in the world and that this collaboration on the development of treatments could redefine how physicians treat this disease in the future.